Biotech Business - May 13, 2022
Hansa Biopharma announces temporary marketing authorization in Switzerland
Hansa Biopharma has announces that the Swiss Agency for Therapeutic Products (Swissmedic) has granted temporary marketing authorization for Idefirix in adult patients with a positive crossmatch against an available organ from a diseased donor. The use of Idefirix in Switzerland is reserved for patients with a low probability of being transplanted within the framework of […]
Biotech Business - May 5, 2022
BioInvent receives milestone payment
BioInvent International receives a milestone payment from Bayer/Hope Medicine following clinical progression of an out-licensed antibody. BioInvent receives EUR 500,000 following the enrollment of the first patient in a Phase 2 trial of HMI-115 for the treatment of endometriosis in pre-menopausal women. HMI-115 is an anti-prolactin receptor antibody discovered using BioInvent’s n-CoDeR phage display antibody […]
Biotech Business - May 4, 2022
Ilya Pharma announces FDA clearance of IND
Ilya Pharma has announced that FDA have cleared an IND for its lead candidate ILP100-Topical and that the company is immediately accelerating preparations for large adaptive Phase 2 study, designed as a trial. ILP100-Topical is an immunotherapy designed to treat surgical wounds in patients with prediabetes, diabetes and obesity. These patients have weeks to months […]
Biotech Business - April 25, 2022
Ultimovacs receives Notice of Allowance on US Patent
Ultimovacs has received a Notice of Allowance from the United States Patent and Trademarks Office (USPTO) concerning its US patent application on the use of vaccine-checkpoint inhibitor combinations to treat cancer. Subject to grant formalities, it is expected that a patent will issue with a patent term up to at least June 2037. Ultimovacs has […]
Acquisition - April 20, 2022
Ilya Pharma makes strategic investment in bioanalytical company
Ilya Pharma has made a strategic investment in its supply chain to facilitate development of its ILP pipeline by acquiring one of its long-term partners, Nordic Bioanalysis. Founded in 2010, Nordic Bioanalysis have established a strong reputation both in the Nordics and internationally as experts in bioanalytical development and validation for pharmaceuticals, classic small molecules […]
Biotech Business - March 29, 2022
XNK Therapeutics raises 132 million SEK
The company has secured a private placement, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development in multiple myeloma and other indications. The company’s lead investigational candidate drug is currently being evaluated in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab) in […]
